#United States #New York #Pomerantz Law Firm #Sarepta Therapeutics #ELEVIDYS

Pomerantz Law Firm Investigation into Sarepta Therapeutics

Pomerantz LLP, a prominent law firm recognized for its work in corporate and securities litigation, has launched an investigation concerning
Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This probe is aimed at determining whether Sarepta, along with certain executives, may have engaged in unlawful practices that could amount to securities fraud.

Context of the Investigation

The investigation arises amidst shocking news related to Sarepta's Duchenne muscular dystrophy drug, Elevidys. On March 18, 2025, the company released a press statement that revealed a tragic event: the death of a young man suffering from Duchenne muscular dystrophy, who experienced acute liver failure post-treatment with Elevidys. This alarming announcement was met with swift and detrimental repercussions on Sarepta's stock, which plummeted by over 27% that same day, closing at $73.54 per share.

In an equally disturbing turn of events, on June 16, 2025, Sarepta notified the market of a second death connected to acute liver failure in another patient undergoing treatment with Elevidys. This incident caused Sarepta to halt its ongoing clinical trials and temporarily suspend the distribution of Elevidys for patients unable to walk. Following this revelation, Sarepta's stock price fell dramatically once more, this time by 42.12%, closing at just $20.94 per share.

The Implications for Investors

The financial impact of these disclosures has raised critical questions regarding the practices of Sarepta management and whether there was potential knowledge of these dangers prior to the public announcements. Investors are particularly concerned if the company misled them or failed to provide adequate warnings about the risks associated with Elevidys.

Pomerantz LLP is urging any affected investors to step forward and seek legal advice. Those interested in joining potential class action litigation against Sarepta can reach out to Danielle Peyton at 646-581-9980, ext. 7980, or via email. The firm is well-established, with offices in several major cities including New York and London, having a rich history of fighting for the rights of investors and victims of securities fraud.

About Pomerantz LLP

Pomerantz LLP has distinguished itself as one of the leading firms in class action litigation. Founded over 85 years ago by Abraham L. Pomerantz, the firm has a legacy of championing cases of securities fraud, corporate misdeeds, and fiduciary breaches. They have successfully recovered multimillion-dollar settlements for their clients and continue in the tradition of advocating for justice in the financial sector.

With its combination of legal expertise and commitment to defining corporate accountability, Pomerantz LLP strives to ensure that investors' rights are protected amidst complex legal landscapes. Their current investigation into Sarepta Therapeutics is a testament to their dedication to making corporate practices transparent and just for shareholders.

As developments unfold, investors are encouraged to remain vigilant and informed about any proceedings that may arise as a result of this investigation, as these could have significant implications for the future of Sarepta and its investors.